Previous 10 | Next 10 |
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such ...
CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company ...
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcom...
In its annual selection of selecting constituents, NASDAQ Biotechnology Index added Evelo Biosciences (NASDAQ:EVLO) to its list, effective Dec.20 before market open. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biot...
CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to...
The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Me...
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a firesi...
Shares of Evelo Biosciences (EVLO +22.7%) are up this morning after Chardan Capital Markets upgraded the stock from neutral to buy. Analyst Keay Nakae is maintaining the price target at $12 (~36% upside). The company's lead candidate, EDP1815, is in phase 2/3 for COVID-19 and phase 2 for psor...
Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q3 2021 Earnings Call Oct 28, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call Transcript
Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Conference Call October 28, 2021 8:30 AM ET Company Participants Kendra Sweeney - Investor Relations Simba Gill - Chief Executive Officer Mark Plinio - Chief Commercial Officer Jonathan Zung - Chief Development Officer Conference Call Participan...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...